drugset / Trial / NCT07369739
Golidocitinib Combined With Selinexor for CAEBVD
NaSingle-groupOpen-labelTreatment
Summary
This study is a multicenter, prospective, single-arm clinical investigation, with patients with CAEBVD as the main research subjects, to evaluate the effectiveness of the combined treatment regimen of golidocitinib and selinexor.
Timeline
- Start
- 2026-01-01
- Primary completion
- 2027-01-01
- Completion
- 2028-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Golidocitinib | Small molecule | 150 mg | — |
| Subject | Selinexor | Other / unclassified | 40 mg | — |